Five patients with end-stage kidney disease received genetically engineered pig kidneys through an expanded access program, with three maintaining kidney function for over eight months without dialysis and two subsequently transitioning to human donor kidneys. This represents the first documented cases of xenotransplantation functioning as genuine bridge therapy, extending dialysis-free survival while preserving access to human organ transplantation.
Key Points
- Three of five patients maintained pig kidney function beyond eight months without dialysis
- Two patients successfully transitioned from pig to human kidney transplants after dialysis independe
- Genetic edits eliminated rejection triggers and deactivated endogenous retrovirus transmission risk
Longevity Analysis
The ability to extend dialysis-free survival represents a meaningful shift in managing end-stage kidney disease, a condition carrying 60% five-year mortality risk. By preserving organ function without triggering immune rejection, xenotransplantation addresses a critical bottleneck in transplant availability and reduces exposure to dialysis-related morbidity. The successful transition from pig to human kidneys demonstrates that bridge therapy can function without foreclosing better long-term options, fundamentally altering the trajectory for patients facing finite organ supply.
Original published by Longevity.Technology, by Kyle Umipig.